home / stock / fhtx / fhtx articles

FHTX Articles, Foghorn Therapeutics Inc. - From 04/16/24

Stock Information
Company Name: Foghorn Therapeutics Inc.
Stock Symbol: FHTX
Market: NASDAQ
Website: foghorntx.com
Menu
FHTX FHTX Quote FHTX Short FHTX News FHTX Articles FHTX Message Board
Get FHTX Alerts

News, Short Squeeze, Breakout and More Instantly...
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer | Benzinga

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pione...
Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference | Benzinga

CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pione...

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting | Benzinga

Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor...

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909 | Benzinga

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse mode...
Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference | Benzinga

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pionee...

Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher | Benzinga

Foghorn Therapeutics Inc. (NASDAQ:FHTX) shares are trading higher by 44.8% to $4.52 during Thursday’s session after the company announced tha...

Foghorn Therapeutics Announces CFO Departure | Benzinga

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pionee...
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting | Benzinga

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pionee...

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress | Benzinga

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pionee...

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference | Benzinga

Pre-clinical data for selective EP300 supports opportunity in solid and hematologic tumor types FHD-286, a potent, selective inhibitor of BRG1 an...
Previous 10 Next 10